logo

Delmar Pharmaceuticals, Inc. (DMPI)



Trade DMPI now with
  Date
  Headline
5/13/2020 8:03:54 AM DelMar Pharma Q3 Net Loss $1.96 Mln Or $0.17/shr Vs Loss $1.7 Mln Or $0.67/Shr Last Year
5/5/2020 8:20:13 AM DelMar Pharma Provides Enrollment Update In Phase 2 Clinical Trial Of VAL-083 For Adjuvant Treatment Of Brain Tumors
3/26/2020 8:01:38 AM DelMar Pharmas Receives Nasdaq Bid Price Extension Until Sept 21, 2020
3/26/2020 8:00:00 AM DelMar Pharmaceuticals Receives Nasdaq Bid Price Extension (Press Release)
3/4/2020 8:48:06 AM DelMar Says Exceeded 50% Enrollment In Adjuvant Arm Of Ongoing Phase 2 Clinical Study Of VAL-083
2/19/2020 8:08:59 AM DelMar Enrolls Final Patient In Phase 2 Trial Of VAL-083 For First-Line Treatment Of Brain Tumors
1/29/2020 8:15:25 AM DelMar Pharma Announces Peer-Reviewed Publication Of Interim Results Of Phase 2 Clinical Trial Of VAL-083
11/25/2019 9:58:33 AM DelMar : Interim Data Of VAL-083 Shows Favorable Outcomes In Both Recurrent And Newly-Diagnosed GBM
11/14/2019 8:06:01 AM DelMar Pharma Q1 Net Loss $1.6 Mln Or $0.21/shr Vs. Net Loss Of $2.0 Mln Or $0.88/shr Prior Year
9/10/2019 8:07:27 AM DelMar Pharma FY Net Loss Of About $8.0 Mln Or $3.16/shr Vs. Net Loss Of $11.1 Mln Or $5.42/shr Prior Year
9/9/2019 8:11:43 AM DelMar Reports Full Compliance With Nasdaq Listing Criteria
9/4/2019 8:32:20 AM DelMar Pharma Relocates Headquarters To San Diego, California
8/27/2019 8:35:33 AM DelMar Expects Cash Runway Will Provide Capital For Full Enrollment In All Three Patient Groups In Two Phase 2 Trials
8/14/2019 9:12:33 AM DelMar Pharma Announces Pricing Of $6.8 Mln Underwritten Public Offering